BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...

The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...

ALNY reports submitting an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.

NICE' has said that Wainzua can be used as an alternative to Alnylam's Amvuttra (vutrisiran), which was recommended for NHS ...

Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) yesterday and set a price target of ...

Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary ...

On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...

Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary ...

2025 will be a very eventful year for BridgeBio. In addition to the commercial launches of Attruby in the United States, ...

California-based BridgeBio has secured US FDA approval for its lead candidate drug, acoramidis (brand name Attruby) for ...

An open-label extension study of the phase 3 ATTRibute-CM trial shows that acoramidis produced reductions of 36% and 34% in ...

But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...